Código QR (código de barras bidimensional)

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to <40 kg) and 600 mg (≥40 kg) Tixagevimab-Cilgavimab, respecti...

ver descrição completa

Na minha lista:
Principais autores: Jassada Buaboonnam, Supattra Rungmaitree, Nuntawan Piyaphanee, Sirirat Charuvanij, Onsiri Pitisuttithum, Katherine Copeland, Chatkamol Pheerapanyawaranun, Laddawan Jansarikit, Suvimol Niyomnaitham, Kulkanya Chokephaibulkit
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2024-12-01
coleção:Human Vaccines & Immunotherapeutics
Assuntos:
Tixagevimab-cilgavimab
pre-exposure prophylaxis
immunocompromised
children
adolescents
Thailand
Acesso em linha:https://www.tandfonline.com/doi/10.1080/21645515.2024.2428011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados